Myeloid-Derived Suppressor Cells Express Bruton’s Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

Andrew Stiff1,2, Prashant Trikha3, Robert Wesolowski4, Kari Kendra4, Vincent Hsu3, Sarvani Uppati3, Elizabeth McMichael2, Megan Duggan2, Amanda Campbell1,2, Karen Keller3, Ian Landi3, Yiming Zhong5, Jason Dubovsky5, John Harrison Howard6, Liangbo Yu7, Bonnie Harrington5, Matthew Old8, Sean Reiff2,2, Thomas Mace4, Susheela Tridandapani2,6, Natarajan Muthusamy5, Michael A. Caligiuri5, John C. Byrd5, and William E. Carson III9

Abstract

Myeloid-derived suppressor cells (MDSC) are a heterogeneous group of immature myeloid cells that expand in tumor-bearing hosts in response to soluble factors produced by tumor and stromal cells. MDSC expansion has been linked to loss of immune effector cell function and reduced efficacy of immune-based cancer therapies, highlighting the MDSC population as an attractive therapeutic target. Ibrutinib, an irreversible inhibitor of Bruton’s tyrosine kinase (BTK) and IL2-inducible T-cell kinase (ITK), is in clinical use for the treatment of B-cell malignancies. Here, we report that BTK is expressed by murine and human MDSCs, and that ibrutinib is able to inhibit BTK phosphorylation in these cells. Treatment of MDSCs with ibrutinib significantly impaired nitric oxide production and cell migration. In addition, ibrutinib inhibited in vitro generation of human MDSCs and reduced mRNA expression of indolamine 2,3-dioxygenase, an immunosuppressive factor. Treatment of mice bearing EMT6 mammary tumors with ibrutinib resulted in reduced frequency of MDSCs in both the spleen and tumor. Ibrutinib treatment also resulted in a significant reduction of MDSCs in wild-type mice bearing B16F10 melanoma tumors, but not in X-linked immunodeficiency mice (XID) harboring a BTK mutation, suggesting that BTK inhibition plays an important role in the observed reduction of MDSCs in vivo. Finally, ibrutinib significantly enhanced the efficacy of anti-PD-L1 (CD274) therapy in a murine breast cancer model. Together, these results demonstrate that ibrutinib modulates MDSC function and generation, revealing a potential strategy for enhancing immune-based therapies in solid malignancies. Cancer Res; 76(8); 2125–36. © 2016 AACR.

Introduction

Myeloid derived suppressor cells (MDSC) are immature myeloid cells with immunosuppressive properties that expand in tumor-bearing hosts in response to tumor- and stroma-derived factors (1–4). In mice, MDSC are recognized by the expression of GR-1 and CD11b, whereas in humans these cells are considered to be CD33+/CD11b+/HLA-DRlow/neg (3, 5).

MDSC are critical contributors to tumor evasion of immune responses (3, 6, 7). MDSC promote immune suppression by the production of arginase-1, indolamine 2, 3-dioxygenase (IDO), nitric oxide (NO), reactive oxygen species (ROS), suppressive cytokines (e.g., IL10 and TGFβ), and the induction of regulatory T lymphocytes (3, 8). Our group has shown that MDSC-derived NO results in the nitration of proteins involved in interferon receptor signal transduction and reduced responsiveness of immune cells to cytokine stimulation (9).

Given the ability of MDSC to suppress antitumor immune responses, they have received significant interest as biomarkers and therapeutic targets. The frequency of circulating MDSC correlates with tumor burden and has prognostic value in a variety of solid tumors (10–13). Studies in murine tumor models have shown that reduction of MDSC number or function results in reduced tumor growth and improved antitumor immune responses (14, 15). Importantly, targeting MDSC in murine tumor models enhances the efficacy of immune-based therapies such as PD-1/PD-L1 checkpoint blockade (16, 17). To date, a variety of agents have been studied for their ability to eliminate or inhibit MDSC function with limited success in translation to the clinical setting (18). As a result, the identification of safe, easily administered, and effective agents...
targeting MDSC could lead to new therapeutic approaches for a number of malignancies.

Ibrutinib is an orally administered irreversible inhibitor of Bruton’s tyrosine kinase (BTK) and IL2-inducible T-cell kinase (ITK) that is in clinical use for B-cell malignancies. Ibrutinib covalently binds to cysteine residues immediately outside of the ATP-binding pocket of BTK and ITK. Targeting BTK in malignant B cells with ibrutinib has been shown to inhibit B-cell receptor signaling via reduced activation of ERK and PLCγ2 as well as NF-κB signal transduction (19–21). Inhibition of ITK by ibrutinib limits the development of Th2 cells, resulting in a Th1 polarization, which is considered favorable for antitumor immune responses (22, 23).

BTK also plays a role in the maturation, trafficking, and function of myeloid cells (24–26). Ibrutinib impairs TNFα and IL1β production by monocytes in the setting of autoimmune arthritis (27). Reports have also shown a role for BTK in Toll-like receptor (TLR) signaling in myeloid cells, which is of interest because TLR signaling has been implicated in MDSC generation and function (28–30).

As a result, it was hypothesized that MDSC would express BTK, and treatment with ibrutinib would result in altered MDSC function and/or generation in the setting of cancer. In this report, it is demonstrated that MDSC isolated from tumor-bearing hosts express BTK and that ibrutinib inhibited BTK phosphorylation in MDSC. Ibrutinib also altered important functional properties of MDSC, including NO production and migration. In multiple murine tumor models, ibrutinib significantly reduced the frequency of MDSC in vivo and improved the efficacy of anti-PD-1 checkpoint blockade. To our knowledge, this is the first report to demonstrate expression of BTK in MDSC and the ability of ibrutinib to impair the generation and function of MDSC. These findings suggest the exciting potential for ibrutinib to improve immune system function in the setting of solid tumors and provide a rationale for combining ibrutinib with other immune-based therapies.

Materials and Methods

Cell lines

The murine MDSC cell line MSC2 (gift from Gregoire Mignon, University of Burgundy, Dijon, France) was cultured in RPMI 1640 media supplemented with 25 mmol/L HEPES, 10% heat-inactivated fetal bovine serum (FBS), 1% antibiotic–antimycotic, and 1 mmol/L sodium pyruvate (31). The EMT6, 4T1, C26, and B16F10 cell lines were purchased from ATCC. EMT6 was maintained in complete IMDM media. 4T1, C26, and B16F10 were maintained in complete DMEM media. All cell lines used were acquired after 2010 and were validated by karyotyping/cytogenetics.

Murine tumor models

Female, 4- to 6-week-old, BALB/c mice (The Jackson Laboratory) were injected with 10^5 EMT6 or 10^3 4T1 cells in the mammary fat pad to produce tumors. Four- to 6-week-old C57BL/6 mice (The Jackson Laboratory) or BTK mutant X-linked immunodeficiency (XID) mice (from the laboratory of Dr. John C. Byrd, The Ohio State University, Columbus, OH) were injected with 10^5 B16F10 cells subcutaneously (32). XID mice have a single base-pair substitution that alters the conserved Arg28 residue in the N-terminal unique region of unknown function (33). Ibrutinib or vehicle was administered by drinking water at 25 mg/kg daily. Anti-PD-L1 (Bio X cell) was administered intraperitoneally at 100 μg per mouse Monday, Wednesday, and Friday. These studies were conducted under a protocol approved by the Ohio State University’s Institutional Animal Care and Use Committee.

Isolation of MDSC from tumor-bearing mice

Spleens were harvested aseptically from mice, and CD11b^+/Gr-1^+ MDSC were isolated using anti-GR-1 beads (Miltenyi Biotec) with a purity of >95% by flow cytometry.

Isolation of MDSC from peripheral blood of metastatic melanoma patients

Myeloid cells were enriched from peripheral blood using the RosetteSep HLA Myeloid Cell Enrichment Kit (Stemcell Technologies). MDSC were isolated by the subsequent negative selection of HLA-DR^− cells using anti-HLA-DR MicroBeads (Miltenyi Biotec). Samples were acquired following patient signing of informed consent under an Institutional Review Board (IRB)-approved protocol for human subject research (IRB protocol 1999C0348).

In vitro generation of human MDSC

Peripheral blood mononuclear cells (PBMC) were isolated from healthy donor leukopacks (American Red Cross) by Ficoll Hypaque (GE Healthcare) density gradient centrifugation. Monocytes were isolated using CD14 MicroBeads (Miltenyi Biotec) and cultured in RPMI 1640 media supplemented with 10% heat-inactivated pooled human AB serum (HAB; C-Six Diagnostics), 1% antibody–antimycotic, and 10 ng/mL IL6 and GM-CSF (Peprotech). Where indicated, monocytes were treated with 0.01% DMSO or 1 μmol/L of ibrutinib (0.01% DMSO) for 1 hour every day.

Immunoblot analysis

MSC2 cells, murine MDSC, or human MDSC were lysed in RIPA buffer (Sigma). Lysates were probed for phosphorylated BTK (p-BTK) (Cell Signaling Technology), total BTK (Cell Signaling Technology), total ITK (Cell Signaling Technology), total Bmx (Epitomics), or GAPDH (Santa Cruz Biotechnologies) as previously described (23).

Nitric oxide estimation

MSC2 cells or MDSC isolated from metastatic melanoma patients were treated with DMSO or ibrutinib for 1 hour; media were then aspirated and replaced. MSC2 cells were then stimulated with 100 ng/mL LPS for 24 hours (Sigma Aldrich, cat. num. L6529) as previously described (30). Melanoma patient MDSC were cultured with 10 ng/ml IL6 and 10 ng/mL GM-CSF (Peprotech) for 48 hours. Griess reagent (Sigma Aldrich) was used to measure nitrite in supernatants, as previously described (34).

Migration assays

MSC2 cells or MDSC from metastatic melanoma patients were treated with DMSO or ibrutinib for 1 hour. Patient MDSC (1 × 10^5) or MSC2 cells (2 × 10^5) were plated in the top chamber of an 8-μm Transwell assay. Media conditioned by the EMT6 cell line were used to stimulate MSC2 migration, and media supplemented with 200 ng/mL GM-CSF were used stimulate patient MDSC migration. Inserts were collected after 24 hours and stained using the Dip Quick Stain Kit (Jorgensen Laboratories, Inc.).
Photographs were taken using a digital camera, and cell numbers were enumerated using ImageJ software (2,418 × 1,536 pixels; Advanced Microscopy Group). MDSC (2 × 10⁶), isolated from the spleen of EMT6 tumor-bearing mice, were treated as above, and migration assayed as previously described (35). Recombinant murine CXCL12, MIP-1α, and VCAM-1 were purchased from R&D Systems.

Cytokine measurement
MSC2 cells were treated with DMSO or ibrutinib for 1 hour followed by washout and stimulation with LPS. Supernatants were collected after 24 hours, and the levels of cytokines were measured using a flow cytometric murine cytokine bead assay (BD Biosciences).

Real-time PCR
Total RNA was extracted using the TRizol reagent (Life Technologies). Reverse transcription reactions were performed using 500-ng RNA in a 20-μL reaction with the high-capacity reverse transcription kit (Life Technologies). cDNA was used as a template to measure the expression of murine and human Arg1, Idol, Nos2, Ncf1 (p47), and Blk genes by quantitative real-time PCR using predesigned primers (Integrated DNA Technologies). Murine and human β-actin served as an internal control for each reaction (Life Technologies). Real-time PCR reactions were performed using the ABI PRISM 7900HT fast Real Time PCR system with SYBR Green chemistry (Applied Biosystems).

Flow cytometric analysis of murine and human MDSC
Spleens and tumors from mice were processed into single-cell suspensions and stained with Alexa 488 anti-GR-1 and APC anti-CD11b antibodies (BD Biosciences). Single-cell suspensions from mouse spleens were also stained with fluorochrome-labeled antibodies against CD19 and B220 (BD Biosciences). In vitro-generated human MDSC were harvested using non-enzymatic cell dissociation solution (Sigma Aldrich) and stained with APC anti-CD33, PE anti-CD11b, and PE/Cy7 anti-HLA-DR antibodies (Beckman Coulter). Data were acquired using an LSRII flow cytometer (BD Biosciences).

Murine carboxyfluorescein diacetate succinimidyl ester assay
MDSC were isolated from the spleen of EMT6 tumor-bearing mice, and T cells were isolated from a non–tumor-bearing mouse using the murine T-cell isolation kit (Stemcell Technologies). Donor monocytes were treated with DMSO or ibrutinib followed by incubation overnight with 10 ng/mL IL6 and GM-CSF. T cells were labeled with carboxyfluorescein diacetate succinimidyl ester (CFSE; Life Technologies) and incubated overnight with 10 ng/mL IL2 (Peprotech). T cells were nonspecifically activated with anti-CD3/CD28 beads (Life Technologies) and cocultured at 1:1, 2:1, and 4:1 ratios of T cells to MDSC. After 3 days, T-cell proliferation was assessed by flow cytometry. APC anti-CD4 and anti-CD8 antibodies were used to identify T-cell subsets (Biolegend).

Statistical analysis
Statistical differences between treatment groups were determined using an ANOVA model and Student t test. For mice tumor studies, a linear mixed model was used to model longitudinal tumor volume for mice under each treatment. Comparisons were done at each time point and averaged across all time points using t statistics. The Holm–Bonferroni method was used for adjusting raw P values for multiple comparisons across treatment groups.

Results
Murine and human MDSC express BTK
Given the role of BTK in the differentiation and function of myeloid cells, it was hypothesized that MDSC would express BTK. To test this, BTK expression was measured in MDSC isolated from Balb/c mice bearing EMT6 and 4T1 mammary carcinoma tumors. As seen in Fig. 1A, BTK was expressed by MDSC from both tumor models, but MDSC from the EMT6 model showed higher BTK expression. To investigate this difference, the expression of BTK at the mRNA level was measured by qRT-PCR in FACs-sorted granulocytic (G-MDSC) and monocytic (M-MDSC) MDSC subsets. M-MDSC showed more BTK expression than G-MDSC in both tumor models. In addition, there was higher BTK expression in both MDSC subsets from the EMT6 model compared with the 4T1 model (Supplementary Fig. S1A). In addition, analysis of the MDSC subsets by flow cytometry showed a higher frequency of the M-MDSC subset in the EMT6 model (Supplementary Fig. S1B). The combination of higher BTK expression and frequency of M-MDSC in the EMT6 model likely explains the difference in BTK expression between these models. The murine MDSC cell line MSC2 and MDSC isolated from Balb/c mice with C26 colon carcinoma tumors also expressed high levels of BTK (Supplementary Fig. S1C). In addition, MDSC isolated from metastatic melanoma patients as well as human MDSC generated in vitro from monocytes expressed BTK (Fig. 1B).

The ability of ibrutinib to inhibit the phosphorylation of BTK (p-BTK) in MDSC was next determined. The murine MDSC cell line MSC2, which has been shown to phenotypically and functionally resemble the monocytic MDSC subset, was first used (31). MSC2 cells were treated with DMSO or ibrutinib at doses ranging from 0.01 μmol/L to 1 μmol/L for 1 hour followed by stimulation with 100 ng/mL of LPS (TLR 4 agonist) for 4 hours, and the level of p-BTK was assessed by immunoblot. These experiments revealed that BTK was constitutively phosphorylated in MSC2 cells, but treatment with ibrutinib inhibited p-BTK even at the 0.01 μmol/L dose in the presence or absence of LPS stimulation (Fig. 1C and Supplementary Fig. S1D). In a similar set of experiments, human MDSC generated in vitro from healthy donor monocytes were treated with DMSO or ibrutinib followed by treatment with 10 ng/mL of IL6 and GM-CSF. In vitro–generated human MDSC were found to express high levels of p-BTK that was not further enhanced by IL6 and GM-CSF. However, similar to MSC2 cells, ibrutinib treatment resulted in a decrease in the level of p-BTK (Fig. 1D).

Ibrutinib does not induce apoptosis of murine or human MDSC
MSC2 cells, melanoma patient MDSC, and in vitro–generated MDSC were treated with various concentrations of ibrutinib, and cell viability was determined 24 hours later by annexin/PI staining. Treatment with ibrutinib resulted in a slight increase in the frequency of apoptotic MSC2 cells, but this effect was not statistically significant. Likewise, ibrutinib was not cytotoxic to human MDSC. Trypan blue exclusion also showed no effect of ibrutinib on MDSC viability (Supplementary Fig. S2 and data not shown).
Gene expression and cytokine production in MSC2 cells following ibrutinib treatment

The effect of ibrutinib on the expression of genes known to mediate immune suppression by MDSC was examined. MSC2 cells were treated with DMSO or ibrutinib for 1 hour followed by activation with LPS. Cells were harvested 24 hours later, and the relative expression of arginase-1 (Arg1), indolamine 2, 3-dioxygenase-1 (Ido1), inducible nitric oxide synthase-2 (Nos2), and neutrophil cytosolic factor-1 (Ncf1 or p47) mRNA was determined by qRT-PCR. Treatment with ibrutinib caused Arg1 and Nos2 expression to trend lower while Ido1 and Ncf1 trended toward increased expression, but none of these differences were statistically significant (Fig. 2A). In addition, the expression of these genes was measured in MDSC isolated from the spleen of EMT6 tumor-bearing mice treated with ibrutinib or vehicle. This analysis showed similar trends in expression of these genes following treatment with ibrutinib as the MSC2 cells (Supplementary Fig. S3).
Supernatants from parallel treatments of MSC2 cells were collected and cytokine production measured using a flow cytometry cytokine bead assay. LPS treatment induced the release of IL6 and TNFα, whereas production of IL10 was not significantly affected. Ibrutinib significantly reduced TNFα production at all doses tested, but had no impact on IL6 secretion (P < 0.05; Fig. 2B and C). These findings are consistent with the reported role of BTK in promoting stabilization of TNFα mRNA but not IL6 mRNA following TLR4 stimulation (36). As IL6 is known to drive the expression of MDSC immune suppressive genes, such as Arg1 and Ido1, the lack of a change in IL6 secretion following ibrutinib treatment is consistent with the data showing no significant change in the expression of these genes.

Ibrutinib reduces murine and human MDSC NO production and migration

NO is a key molecule produced by MDSC that is involved in mediating immune suppression (9). As a result, the ability of ibrutinib to reduce NO production by murine and human MDSC was tested. MSC2 cells were treated with ibrutinib followed by stimulation with LPS. Supernatants were harvested 24 hours later, and nitrite levels were quantified using the Griess reagent as described (34). Ibrutinib treatment led to decreased NO production that reached statistical significance at the 1 μmol/L dose (P < 0.05; Fig. 3A). Similarly, treatment of MDSC isolated from metastatic melanoma patients with ibrutinib resulted in a significant decrease in NO production compared with DMSO-treated controls (Fig. 3B).

To promote local immune suppression, MDSC must migrate into the tumor microenvironment, and disruption of this process may affect antitumor immune responses (4, 17). Notably, ibrutinib has been shown to impair the chemotaxis of malignant B cells (35). To investigate the ability of ibrutinib to impair MDSC migration, MSC2 cells were treated with various doses of ibrutinib and plated in a Transwell assay with EMT6 cancer cell–conditioned media as a stimulus for migration. These experiments showed that ibrutinib significantly reduced MSC2 migration at...
Ibrutinib reduces MDSC NO production and migration

Given the ability of ibrutinib to attenuate MDSC NO production and migration, it was hypothesized that treatment of MDSC with ibrutinib would reduce their ability to suppress T-cell proliferation. To test this, MDSC isolated from the spleens of EMT6 tumor-bearing mice were treated with DMSO or ibrutinib and cocultured with CFSE-labeled T cells isolated from healthy mice that were activated with anti-CD3/CD28 beads. After 3 days, T-cell proliferation was assessed by flow cytometry, and it was found that CD8\(^+\) T cells cultured with ibrutinib-treated MDSC showed significantly more proliferation than those cultured with DMSO-treated MDSC (12.49% vs. 21.98%, \(P < 0.05\); Fig 4A). There was also a trend toward increased CD4\(^+\) T-cell proliferation in the presence of ibrutinib-treated MDSC as compared with control-treated MDSC, but this result did not reach statistical significance (Fig 4B).

Ibrutinib inhibits in vitro generation of human MDSC from healthy donor monocytes

BTK signaling has been shown to play a role during the differentiation of myeloid cell subsets (24, 38). In particular, BTK plays a negative role in the maturation of dendritic cells; BTK-deficient dendritic cells have high HLA-DR expression compared with wild-type counterparts (39). As a result, it was hypothesized that BTK inhibition with ibrutinib could limit the generation of human MDSC by promoting HLA-DR expression.

the 0.5 \(\mu\)mol/L dose (\(P < 0.05\); Fig. 3C). Similarly, MDSC isolated from patients with metastatic melanoma were treated with DMSO or 1 \(\mu\)mol/L ibrutinib and migration stimulated using media supplemented with 200 ng/mL GM-CSF. Results from these experiments revealed that ibrutinib also significantly inhibited the migration of human MDSC (\(P < 0.05\), Fig. 3D). To validate these findings, the ability of ibrutinib to impair MDSC migration in response to the chemokines CXCL12 (SDF-1) and CCL3 (MIP-1\(\alpha\)) was tested, as previously described (35). Ibrutinib was able to inhibit MDSC migration in response to SDF-1, but not MIP-1\(\alpha\) (Supplementary Fig. S4 and data not shown). Importantly, SDF-1 has previously been shown to regulate MDSC accumulation within tumors (37). In addition, ibrutinib significantly reduced the expression of CD49D and CD11a, adhesion molecules known to play a role in myeloid cell migration, whereas expression of CD11b and CD62L was unaffected (Supplementary Figs. S5A-S5D). This reduction in adhesion molecule expression could provide an explanation for the observed reduction in MDSC migration.

Ibrutinib reduces MDSC suppression of T-cell proliferation

Given the ability of ibrutinib to attenuate MDSC NO production and migration, it was hypothesized that treatment of MDSC from metastatic melanoma patients were treated with DMSO or ibrutinib for 1 hour. After treatment, MDSC were cultured with 10 ng/ml IL-6 and 10 ng/ml GM-CSF for 48 hours and nitrite measured as above. Values, mean ± SE from three patients; \(P < 0.05\). C, MSC2 cells were treated with DMSO or ibrutinib for 1 hour. Media conditioned by the EMT6 cell line served to stimulate migration. Values, mean ± SE from three independent experiments; \(P < 0.05\). D, MDSC isolated from patients with melanoma were treated with DMSO or ibrutinib. 200 ng/ml GM-CSF was used to stimulate chemotaxis and PBS supplemented media served as a negative control. Migration proceeded for 12 hours. Values, mean ± SE from three patients. Representative images are given below migration results. Migrated cells are stained purple against the light blue Transwell insert.

Published OnlineFirst February 15, 2016; DOI: 10.1158/0008-5472.CAN-15-1490

Downloaded from cancerres.aacrjournals.org on January 22, 2018. © 2016 American Association for Cancer Research.
To test this hypothesis, three experimental conditions were used: (i) monocytes cultured without cytokines and treated daily with DMSO (control), (ii) monocytes cultured with IL6 and GM-CSF treated daily with DMSO, (iii) monocytes cultured with IL6 and GM-CSF treated daily with 1 μmol/L ibrutinib. Six-day culture of human monocytes in IL6 and GM-CSF produced a significant increase in CD33⁺/CD11b⁺/HLA-DRlow MDSC (46.2%, P < 0.05; Fig. 5A and B). Importantly, these cells were fully able to suppress T-cell proliferation (Supplementary Fig. S6). Daily treatment with ibrutinib reduced MDSC to levels comparable with those in the no-cytokine control culture (12.49%, P < 0.05; Fig. 5A and B).

Expression of Arg1, Ido1, Nos2, and Ncf1 (p47) in these treatment groups was measured by qRT-PCR on day 6 of culture. Ibrutinib treatment resulted in a significant reduction in Ido1 transcript (P < 0.05, Fig. 5C), whereas expression of Arg1, Nos2, and Ncf1 (p47) was lower than that of cells cultured with IL6 and GM-CSF treated with DMSO, but not in a statistically significant manner. These results are in contrast to those reported in Fig. 2, where ibrutinib did not significantly alter the expression of these genes in cells that already possessed a MDSC phenotype. This may indicate that ibrutinib has a more potent ability to block the development of MDSC than impair the expression of immune suppressive genes by MDSC.

Ibrutinib reduces the frequency of MDSC in tumor-bearing mice

The effect of ibrutinib treatment on MDSC in vivo was evaluated next. Immune competent Balb/c mice bearing EMT6 murine mammary carcinoma tumors were treated with ibrutinib (25 mg/kg daily) or vehicle via drinking water as previously reported (23). At the end of the study, spleens and tumors were analyzed for the presence of MDSC. Ibrutinib treatment resulted in a significant reduction of CD11b⁺/GR-1⁺ MDSC in both the spleen and tumor (P < 0.05, Fig. 6A). This reduction in MDSC was accompanied by a significant reduction in spleen weight,
suggesting reduced extra-medullary myelopoiesis (Supplementary Fig. S7A; ref. 40). Importantly, no difference in B220^+ /CD19^+ B-cell frequency in the spleen was observed after ibrutinib treatment, indicating that ibrutinib was able to specifically deplete MDSC (Supplementary Fig. S7B). Ibrutinib-treated mice also showed a small reduction in tumor volume, but this difference was not statistically significant (Fig. 6B). MDSC levels are known to correlate with tumor burden. As a result, the lack of a difference in tumor volume between vehicle- and ibrutinib-treated mice suggests that the reduction of MDSC frequency is a direct result of ibrutinib, and not simply a reflection of differences in tumor burden. In addition, EMT6 cancer cells do not express BTK, thus likely excluding a direct antitumor effect of ibrutinib in this model (Supplementary Fig. S7C).

To further confirm the ability of ibrutinib to reduce the frequency of MDSC in vivo, C57BL/6 mice inoculated with B16F10 melanoma cells were treated with vehicle or ibrutinib as above once tumors had successfully engrafted (5-mm diameter). Similar to the results obtained with the EMT6 mammary carcinoma model, ibrutinib treatment did not significantly affect B16F10 tumor growth (Supplementary Fig. S8), but it did result in a significant reduction in the frequency of GR-1^- / CD11b^- MDSC in the spleen of B16F10 tumor-bearing hosts (Fig. 6C).

While ibrutinib is a potent inhibitor of BTK, it is also known to effectively inhibit several other kinases, including ITK, Bmx, and Blk. To investigate the specific role of BTK inhibition in the observed reduction of MDSC in tumor-bearing hosts, XID mice that have a point mutation in BTK were utilized. It was hypothesized that if additional kinases, besides BTK, played an important role in the observed reduction of MDSC in tumor-bearing hosts, then BTK-mutant XID mice treated with ibrutinib would also show a significant reduction of MDSC. To test this hypothesis, XID mice were engrafted with B16F10 melanoma tumors and treated...
Ibrutinib Impairs MDSC Generation and Function

Figure 6. Ibrutinib reduces MDSC frequency in vivo. Eight mice were included in the ibrutinib treatment group and 10 mice in the vehicle control group. A. splenocytes and single-cell suspensions of the tumors were stained with Gr-1 and CD11b antibodies. Values, mean ± SE of Gr-1+/CD11b+ MDSC in the spleen and tumor; *, P < 0.05. B, tumor volumes were measured three times weekly. Values, mean ± SE of tumor volumes at each time point. C, wild-type C57BL/6 mice were inoculated with 1 × 10⁵ B16F10 melanoma cells subcutaneously. After 2 weeks of treatment, mice were sacrificed, and the frequency of Gr-1+/CD11b+ MDSC in the spleen was measured by flow cytometry. Values, mean ± SE of MDSC from 5 mice for each treatment group; P < 0.05. D, BTK-mutant C57BL/6 XID mice were inoculated with 1 × 10⁵ B16F10 melanoma cells subcutaneously. After 2 weeks of treatment, mice were sacrificed, and the frequency of Gr-1+/CD11b+ MDSC in the spleen was measured by flow cytometry. Values, mean ± SE of MDSC from 5 mice for each treatment group; P = 0.73.

with vehicle or ibrutinib, as described above. After 2 weeks, the mice were sacrificed, and the frequency of splenic MDSC was determined by flow cytometry. This analysis revealed that treatment of XID mice with ibrutinib did not significantly reduce MDSC frequency in the spleen compared with vehicle-treated XID mice (Fig. 6D). This suggests that BTK inhibition by ibrutinib plays an important role in the observed reduction of MDSC in EMT6 and B16F10 tumor-bearing hosts. To further clarify the potential off-target effects of ibrutinib, the expression of Bmx and Itk was measured by immunoblot analysis. No significant expression was observed in mouse and human MDSC (Supplementary Figs. S9A and S9B). In addition, Btk expression by mouse and human MDSC was measured by qRT-PCR, and only low levels of expression were detected (Supplementary Figs. S9C and S9D). However, these results do not completely rule out the possibility that inhibition of alternative kinases, besides BTK, also plays some role in the effect of ibrutinib on MDSC, given that the frequency of MDSC in ibrutinib-treated XID mice was lower than that in vehicle-treated XID mice.

Ibrutinib improves the efficacy of immune-based cancer therapies

Given previous reports of strategies that target MDSC leading to enhanced efficacy of immune checkpoint blockade, the ability of ibrutinib to improve anti-PD-L1 therapy was tested (17). For this study, Balb/c mice were inoculated with EMT6 mammary carcinoma cells as above. Once tumors were palpable (5-mm diameter), mice were treated with vehicle/IgG as control, ibrutinib (25 mg/kg daily), anti-PD-L1 antibody (100 µg/mouse), or the combination of ibrutinib and anti-PD-L1. As shown in Fig. 7, the combination of ibrutinib and anti-PD-L1 produced a significant reduction in tumor growth compared with either agent alone (P < 0.05 and P < 0.01; Fig. 7). In addition, 50% of mice in the combination treatment group showed a complete response compared with 11.1% with anti-PD-L1 alone. Importantly, all mice that had a complete response are still tumor free 6 weeks after the last treatment.

Discussion

BTK is a key component of B-cell receptor signaling, but it is now being recognized that BTK also plays a role in the function of other immune cells (24). This work evaluated the expression of BTK in MDSC and the effect of a BTK inhibitor, ibrutinib, on MDSC function and generation. BTK was found to be highly expressed by MDSC isolated from multiple tumor models and human MDSC. Ibrutinib was able to inhibit the phosphorylation of BTK in both murine and human MDSC. Furthermore, ibrutinib reduced NO production and migration of MDSC. Ibrutinib also inhibited the in vitro generation of human MDSC, which was associated with reduced expression of Ido1 mRNA in these cultures. Using mouse models of breast cancer and melanoma, ibrutinib treatment resulted in a significant reduction of MDSC in vivo. However, ibrutinib treatment of XID mice expressing a nonfunctional mutant form of BTK engrafted with B16F10 melanoma tumors showed no significant reduction of MDSC.
Ibrutinib improves anti-PD-L1 immune checkpoint blockade. Once tumors were palpable (5-mm diameter), mice were divided into four treatment groups: vehicle/IgG control, ibrutinib (25 mg/kg daily), anti-PD-L1 (100 μg per mouse Monday, Wednesday, and Friday), or the combination of ibrutinib and anti-PD-L1 therapy. Nine to 10 mice were included in each treatment group. Tumor volumes were measured three times weekly with digital calipers. Treatment with the combination of ibrutinib and anti-PD-L1 resulted in a significant reduction in tumor growth compared with treatment with ibrutinib (*, P < 0.01) or anti-PD-L1 (**, P < 0.05) alone.

compared with vehicle-treated XID mice. Finally, ibrutinib was able to improve the efficacy of anti-PD-L1 immune checkpoint blockade, a T-cell–directed therapy.

Ibrutinib, an irreversible inhibitor of BTK, is clinically used for the treatment of B-cell malignancies. Inhibition of BTK via ibrutinib impairs the activation of signaling pathways important to malignant B cells, including the B-cell receptor and NF-κB pathways (19, 20). Several reports have demonstrated the ability of ibrutinib to alter the activation and function of immune cell subsets, including basophils, monocytes, and T helper cells, indicating that ibrutinib has broader immune modulatory effects (41). The current work builds on these studies by showing that MDSC express BTK and that their generation/function can be inhibited by ibrutinib.

To date, four strategies have been used to target MDSC: depletion, deactivation, differentiation, or the blockage of development (18). Depletion of MDSC has been studied using MDSC–specific depleting peptides, pleiotropic agents such as epigenetic modifiers, and nonspecific chemotherapeutic agents (42–44). Inhibitors of NO, arginase, and ROS have been used to deactivate MDSC function (18). In addition, agents such as CSF-1R inhibitors and inhibitors of chemokine signaling have been used to block MDSC migration into tumors (17, 18). Finally, several groups have studied the ability of kinase inhibitors, such as sunitinib, or inhibitors of transcription factors (e.g., STAT3) to block MDSC generation (18, 45–47). Results from the present study show that ibrutinib has the ability to reduce NO production and migration and inhibit the generation of MDSC. These characteristics make ibrutinib a potentially promising therapeutic agent to target MDSC.

These findings are of particular interest given a recent report by Sagiv-Barfi and colleagues that showed ibrutinib enhanced the antitumor effect of PD-L1 immune checkpoint blockade (48). However, using the 4T1 mammary carcinoma model, ibrutinib did not significantly alter the frequency of MDSC. The authors concluded that the action of the combination therapy was not due an effect on MDSC, but the result of direct activation of T cells (23, 48). The results of this study are consistent with those of Sagiv-Barfi and colleagues in that the combination of ibrutinib and anti-PD-L1 therapy shows improved efficacy, the discrepancy between our findings of reduced MDSC frequency in tumor-bearing mice treated with ibrutinib and the lack of this effect observed by Sagiv-Barfi and colleagues could be explained by differences in the dose, duration, and route of ibrutinib administration and/or the tumor models.

Notably, in the study by Sagiv-Barfi and colleagues, ibrutinib was delivered by intraperitoneal injection at a dose of 6 mg/kg daily for 8 days, whereas in the current study ibrutinib was delivered orally at a dose of 25 mg/kg daily for 2 weeks. It is possible that the lower dose and shorter treatment duration was insufficient to have an effect on MDSC number. Significant differences between the 4T1 and EMT6 models have also been reported (49). The 4T1 model is associated with significantly higher IL6 levels and recruits more MDSC to primary tumor and metastatic sites compared with the EMT6 model (49). In addition, Sagiv-Barfi and colleagues did not examine the effect of ibrutinib on the function of MDSC. The results of the current study show that ibrutinib can modulate MDSC function and development, demonstrating several potential mechanisms by which ibrutinib could improve T-cell function. Importantly, the improved CD8+ T-cell proliferation in the presence of ibrutinib-treated MDSC suggests that ibrutinib results in improved immune function through impairment of MDSC function.

In conclusion, this report demonstrates that murine and human MDSC express BTK, and that ibrutinib is able to inhibit the phosphorylation of BTK in these cells. Treatment of MDSC with ibrutinib results in impaired NO production, migration, and generation of MDSC in vitro. In addition, ibrutinib treatment of tumor-bearing mice resulted in a significant reduction of MDSC and improved the antitumor effect of anti-PD-L1 checkpoint blockade. Thus, ibrutinib-induced suppression of MDSC function and generation could potentially enhance the efficacy of immune-based therapies such as cancer vaccines, cytokine therapy, and checkpoint blockade, potentially leading to novel combination therapies for testing in clinical trials.

Disclosure of Potential Conflicts of Interest
J. Dubovsky is a scientist at Pharmacyclics, an AbbVie Company. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: A. Stiff, P. Trikha, S. Tridandapani, N. Muthusamy, J.C. Byrd, W.E. Carson III
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): A. Stiff, P. Trikha, R. Wesolowski, K. Kendra, V. Hsu, S. Uppati, E. McMichael, M. Duggan, A. Campbell, K. Keller, I. Landi, Y. Zhong, J. Dubovsky, J.H. Howard, M. Old
Analysis and interpretation of data (e.g., statistical analysis, biostatistics, computational analysis): A. Stiff, P. Trikha, R. Wesolowski, K. Kendra, M. Duggan, A. Campbell, J. Dubovsky, L. Yu, N. Muthusamy, J.C. Byrd, W.E. Carson III
Writing, review, and/or revision of the manuscript: A. Stiff, P. Trikha, R. Wesolowski, M. Duggan, A. Campbell, Y. Zhong, L. Yu, N. Muthusamy, M.A. Caligiuri, J.C. Byrd, W.E. Carson III
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): S. Uppati
Study supervision: W.E. Carson III
Other (tissue/blood procurement): J.H. Howard
Grant Support
This work was supported by NIH grants P01CA54262, K24 CA193670 (W.E. Carson), T32CA90338-27 (W.E. Carson), and P01 CA160584 (W.E. Carson, S. Trindadapani, J.C. Byrd, and M.A. Caliguiri), Translational grant K12 CA133250 in experimental therapeutics National Cancer Institute (R.C. Wesołowski), and Ohio State Translational Therapeutics Award TT142 (W.E. Carson).

References

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 29, 2015; revised December 8, 2015; accepted December 23, 2015; published OnlineFirst February 15, 2016.
Myeloid-Derived Suppressor Cells Express Bruton's Tyrosine Kinase and Can Be Depleted in Tumor-Bearing Hosts by Ibrutinib Treatment

Andrew Stiff, Prashant Trikha, Robert Wesolowski, et al.


Updated version Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-15-1490

Cited articles This article cites 48 articles, 25 of which you can access for free at:
http://cancerres.aacrjournals.org/content/76/8/2125.full#ref-list-1

Citing articles This article has been cited by 5 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/76/8/2125.full#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/76/8/2125.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.